BMS Opdivo fails in brain cancer study

Bristol-Myers Squibb said its blockbuster cancer immunotherapy, Opdivo, failed to meet a main goal of a late-stage trial, testing it in patients with a rare type of brain cancer.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news